Everything below concerns Thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
In southwestern Germany, territorial revision seemed to be a top priority since the border between the French and American occupation zones was set along the Autobahn Karlsruhe-Stuttgart-Ulm (today the A8). Article 118 stated "The division of the territory comprising Baden, Württemberg-Baden and Württemberg-Hohenzollern into Länder may be revised, without regard to the provisions of Article 29, by agreement between the Länder concerned. If no agreement is reached, the revision shall be effected by a federal law, which shall provide for an advisory referendum." Since no agreement was reached, a referendum was held on 9 December 1951 in four different voting districts, three of which approved the merger (South Baden refused but was overruled, as the result of total votes was decisive). On 25 April 1952, the three former states merged to form Baden-Württemberg.
Heavy menstrual periods Endometriosis and chronic pelvic pain Adenomyosis and dysmenorrhea Anemia Endometrial hyperplasia (especially in pre-menopausal people who wish to maintain fertility in the treatment of endometrial hyperplasia) In some cases, use of a hormonal IUD may prevent a need for a hysterectomy. Advantages:
=== Rabbits and goats === In 2016, the CRISPR/Cas9 system was used to genetically engineer rabbits and goats with no functional copies of the myostatin gene. In both cases the resulting animals were significantly more muscular. However, rabbits without myostatin also exhibited an enlarged tongue, a higher rate of still births, and a reduced lifespan.
Sources: en.wikipedia.org
== Function == Amino acid catabolism results in waste ammonia. All animals need a way to excrete this product. Most aquatic organisms, or ammonotelic organisms, excrete ammonia without converting it. Organisms that cannot easily and safely remove nitrogen as ammonia convert it to a less toxic substance, such as urea, via the urea cycle, which occurs mainly in the liver. Urea produced by the liver is then released into the bloodstream, where it travels to the kidneys and is ultimately excreted in urine. The urea cycle is essential to these organisms, because if the nitrogen or ammonia is not eliminated from the organism it can be very detrimental. In species including birds and most insects, the ammonia is converted into uric acid or its urate salt, which is excreted in solid form. Further, the urea cycle consumes acidic waste carbon dioxide by combining it with the basic ammonia, helping to maintain a neutral pH.
In 1977, the exiled Republicans accepted the re-establishment of the monarchy and recognised Juan Carlos's government as the legitimate government of Spain. The key moment came when socialist leaders Felipe González and Javier Solana met Juan Carlos at Zarzuela Palace in Madrid — a tacit endorsement of the monarchy by the previously staunchly republican Socialists. On 1 July 1977, the Government of the Spanish Republic was formally dissolved. In a gesture of reconciliation, Juan Carlos received the exiled leaders at a ceremony in Madrid.
==== Mesopotamia ==== According to the expert on Middle Eastern history of chemistry Martin Levey, potassium alum is one of the few compounds known to the ancients that can be found relatively pure in nature, as well as one of only a few chemicals used in Mesopotamian chemical technology that can be identified with certainty. Both native and imported potassium alum was used. Together with other agents, potassium alum was used in glass-making, tanning, and in the dyeing of cloth, wood, and possibly hair. A tanning process using potassium alum is described in tablets from the first millennium BCE. When Levey wrote his article in 1958, no description of the dyeing process had been found, so it is not known how potassium alum was used in it. In Mesopotamian medicine potassium alum was used extensively, for example against itch, jaundice, some eye condition, and unidentified ailments. According to Levey, potassium alum was used in "classical times" as a flux when soldering copper, in the fireproofing of wood, and in the separation of silver and gold, but that there is no evidence that these uses existed in Mesopotamia.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.